<DOC>
	<DOC>NCT00694213</DOC>
	<brief_summary>The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. Subjects will receive 2 vaccinations with the BiojectorÂ® 2000, and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. The safety and immune system's response will be studied throughout the trial.</brief_summary>
	<brief_title>Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 to 45 years of age Able to provide informed consent and be followed for 6 months No immunomodulatory therapy within the past 6 months No evidence of immunodeficiency or pregnancy No laboratory or evidence of clinically significant medical disease No history of previous pDNA immunization No influenza immunization within the past 30 days No blood donations within 30 days of screening visit No history of bleeding disorder No use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Pandemic Influenza</keyword>
	<keyword>Avian Influenza</keyword>
	<keyword>DNA Vaccines</keyword>
	<keyword>Antibody</keyword>
	<keyword>T Cells</keyword>
	<keyword>HA/NP/M2</keyword>
	<keyword>Biojector</keyword>
</DOC>